The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Philip Morris seals deal for UK's Vectura despite health group concerns

Thu, 16th Sep 2021 07:33

* Holders of roughly 75% Vectura shares tender support

* PMI needed 50% backing for deal to go through

* Extends deadline for other holders to tender shares by
Sept. 30
(Adds comment from health group; background on deal)

By Pushkala Aripaka and Siddharth Cavale

Sept 16 (Reuters) - Cigarette maker Philip Morris (PMI)
clinched its 1.1 billion-pound takeover of asthma inhaler
maker Vectura on Thursday, winning the support of the
British company's shareholders despite the concerns of health
professionals.

Vectura's shareholders decided to take the 165
pence-per-share offer from PMI, with nearly 75% backing the
deal.

Buying the London-listed inhaler maker is part of Philip
Morris' long term plan to develop "smoke-free" products and
switch to being a "broader healthcare and wellness" company.

But it has angered health groups such as Asthma UK and the
British Lung Foundation that have questioned whether a tobacco
group should own a company that cures the very respiratory
illnesses cigarettes cause.

PMI Chief Executive Jacek Olczak has argued that acquiring
Vectura is a critical part of his strategy to move the company
"Beyond Nicotine".

He told the Telegraph last month that opponents of the deal
were "not interested in progress" and accused them of "settling
old scores" with the tobacco industry.

Olczak said on Thursday PMI would provide Vectura's
scientists with the resources and expertise to reach its goal of
generating at least $1 billion in net revenue from "Beyond
Nicotine" products by 2025.

In the meantime, Asthma UK and the British Lung Foundation
said they have sent a letter urging the government to look into
any conflict of interest issues.

The letter was co-signed by 35 charities, public health
experts and clinicians.

"There's now a very real risk that Vectura's deal with big
tobacco will lead to the cigarette industry wielding undue
influence on UK health policy," said Sarah Woolnough, Chief
Executive of Asthma UK and the British Lung Foundation.

"We call on the government to stand by its commitment to the
World Health Organization Framework Convention on Tobacco
Control to prevent this happening," Woolnough added.

PMI has received regulatory clearances for the deal and
following the public tender process, its offer cannot now be
withdrawn.

While the company received the 50% threshold to make its
offer unconditional, it has not yet reached the 75% of shares it
needs to delist Vectura.

PMI said it was extending its offer to Sept 30., to give
Vectura shareholders time to accept its proposal.

"Phillip Morris isn't ignoring the elephant; it's making us
all take a long hard look. Discomfort is good, it tends to
deliver change, but care must be taken that the promised change
does come and there are no detours on the journey," AJ Bell
financial analyst Danni Hewson said.
($1 = 0.7234 pounds)
(Reporting by Pushkala Aripaka and Siddharth Cavale in
Bengaluru;Editing by Elaine Hardcastle)

More News
27 May 2020 13:10

UK TRADING UPDATE SUMMARY: Caffyns To Reopen Showrooms As Curbs Ease

UK TRADING UPDATE SUMMARY: Caffyns To Reopen Showrooms As Curbs Ease

Read more
1 May 2020 14:30

Vectura upbeat on EMA nod for 'Enerzair Breezhaler'

(Sharecast News) - Inhalation contract manufacturer Vectura Group noted an announcement from Novartis on Friday, that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of 'Enerzair Breezhaler'.

Read more
23 Mar 2020 09:43

UK BROKER RATINGS SUMMARY: Barclays Raises Pearson, Moneysupermarket

UK BROKER RATINGS SUMMARY: Barclays Raises Pearson, Moneysupermarket

Read more
17 Mar 2020 12:31

Vectura Resilient Against Covid-19 As Flutiform Drives Annual Growth

Vectura Resilient Against Covid-19 As Flutiform Drives Annual Growth

Read more
10 Mar 2020 16:03

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
27 Jan 2020 09:36

UK BROKER RATINGS SUMMARY: Peel Hunt Cuts Ashtead And Raises DCC

UK BROKER RATINGS SUMMARY: Peel Hunt Cuts Ashtead And Raises DCC

Read more
21 Jan 2020 12:48

Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director

Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director

Read more
13 Jan 2020 09:19

Vectura Targeting New Royalties In 2020 As Glaxo Lawsuit Rumbles On

Vectura Targeting New Royalties In 2020 As Glaxo Lawsuit Rumbles On

Read more
13 Jan 2020 08:25

Vectura sees FY revenues and earnings 'at least' in line with expectations

(Sharecast News) - Pharmaceuticals company Vectura said on Monday that its base business had continued to perform well in 2019.

Read more
27 Nov 2019 08:26

TOP NEWS: Hikma Submits Response To Advair Application Deficiencies

TOP NEWS: Hikma Submits Response To Advair Application Deficiencies

Read more
29 Oct 2019 09:41

Vectura Group Hires Former GE Healthcare Exec Will Downie As New CEO

Vectura Group Hires Former GE Healthcare Exec Will Downie As New CEO

Read more
18 Oct 2019 16:06

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
4 Oct 2019 17:31

UPDATE 1-Vectura, Sandoz win ruling on inhaler packaging case against GSK

(Adds comment from GSK spokesman)Oct 4 (Reuters) - Vectura Group said on Friday a British court had ruled in its favour on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.Vectura said the court dismissed all G...

Read more
4 Oct 2019 14:24

High Court Dismisses Glaxo Case Against Generic Seretide Accuhaler

High Court Dismisses Glaxo Case Against Generic Seretide Accuhaler

Read more
3 Oct 2019 16:04

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.